Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

Results of ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) involving 25,620 patients presented today at the 57th Annual Scientific Session of the American College of Cardiology

and published online in the New England Journal of Medicine

CHICAGO, March 31 /PRNewswire/ -- The results of the landmark ONTARGET(TM) trial have demonstrated that MICARDIS(R) (telmisartan), a second-generation angiotensin II receptor blocker (ARB), is equally effective as the current standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in a broad cross-section of high-risk cardiovascular patients with normal blood pressure or controlled high blood pressure, and resulted in fewer discontinuations.(1) These cardiovascular events occurred in 1,423 patients (16.7 percent) receiving telmisartan versus 1,412 patients (16.5 percent) receiving ramipril.(1) The relative risk (ratio of the probability of the event occurring in the telmisartan group versus the ramipril group) was 1.01, with a 95 percent CI of 0.94 - 1.09.

Telmisartan is now the only ARB to have demonstrated cardio and vascular risk reduction benefits beyond lowering blood pressure in this high-risk population;(1) these benefits may be attributed to the specific pharmacological properties and mode of action of the drug. Previously, in 2000, the HOPE trial showed that the cardiovascular risk for patients treated with the angiotensin-converting enzyme (ACE) inhibitor ramipril was reduced by approximately 20 percent compared with placebo.(2) This meant that every fifth serious cardiovascular event in a high risk group of patients was prevented.(2)

"The ONTARGET trial shows that telmisartan is a well-tolerated treatment in high-risk cardiovascular patients that is as effective as ramipril in preventing heart attacks, stroke and hospitalizations for heart failure and dea
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

8

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...AN DIEGO, Nov. 6 Trius Therapeutic...ration statement on Form S-1 with the U.S. Securit...oposed initial public offering of shares of its co...old in the offering will be offered by the Company...ng as sole book-running manager, Piper Jaffray &am...
(Date:11/6/2009)...ARASOTA, Fla., Nov. 6 R...ed that it has signed a definitive agreement to ac...etary medical devices. The Verathon Board of Dire... is subject to customary regulatory approvals and .... The parties expect the closing to be completed ...
(Date:11/6/2009)...RINCETON, N.J., Nov. 6 ..., a provider of advanced wound care products, anno...lts before market on Monday, November 16, 2009. Th...y to discuss the results at 11:00 am EST. Interest...r (857) 350-1684 (international), with passcode 81...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2What Oklahomans Should Know About Cataract Surgery 54775 1What Oklahomans Should Know About Cataract Surgery 54775 2What Oklahomans Should Know About Cataract Surgery 54775 3What Texans Should Know about Cataract Surgery 54773 1What Texans Should Know about Cataract Surgery 54773 2What Texans Should Know about Cataract Surgery 54773 3Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production 13617 1Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production 13617 2
...ompelling case for clinical testing in human ... Nov. 12 In its Oct. 15 issue, Cancer,Research pu...ration,describing successful eradication of human ...ovel oncolytic virus developed by Genelux scientis... for the use of GL-ONC1 in,human cancer patients. ...
...2 Allos,Therapeutics, Inc. (Nasdaq: ALTH ) today... a Phase 1, non-randomized, open-label, multi-cent... chemotherapeutic agent RH1 in,patients with advan... "We are pleased to advance the development of thi...al Officer of Allos. "RH1 is a small molecule,chem...
Other Medicine Technology:Tumor Eradication Article Published by Cancer Research 2Tumor Eradication Article Published by Cancer Research 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 2Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 3Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma 4
(Date:11/8/2009)... UCW Academy of Health holds open ho...Victoria, BC (Vocus) November 8, 2009 -- UCW Acade...eer in British Columbia’s health care indust...sday, November 25, 2009. , ,UCW Academy of Health...ation, nursing and social services, designs its pr...
(Date:11/8/2009)... New book called "Preventing an... Dr. Roberto Giraldo shows that AIDS is a result o...iety of so-called immune system stressor agents, w... and most of all, emotional. , ...m Nov. 6 – 8, 2009, cell biologists, physici...
(Date:11/8/2009)...NGTON, Nov. 7 Today, th...s, Kaptur, Dahlkemper, Smith, Ellsworth and Lipins...erica Act" (H.R. 3962). The amendment maintains th... abortion and for benefits packages that include a... who receive affordability credits and those who d...
(Date:11/8/2009)...s for Swift Passage of H.R. 3961 to Secure the Sta...ire-USNewswire/ -- Statement Attributable to: J. J...ociation. ,, (Logo: http://www.newscom.com/cg...ls the passage of the House health reform bill, wh...ts and physicians and calls for swift passage of H...
(Date:11/8/2009)...WOOD, Calif., Nov. 8 Ma...of Babies luncheon to recognize prominent individu...n and who are role models for March of Dimes commi... the March of Dimes November Prematurity Awareness...re urged to join the fight for preemies! ,, (Ph...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...munochemical faecal occult blood test (FOBT) is a ...ave colorectal cancer, researchers claim in an art...nventionally, guaiac FOBT is used to screen indivi...rectal cancer." Lead author Dr Callum G Fraser ...
...nd more youth belonging to Himachal Pradesh are co...f stress and changing lifestyles.// In the year 20...e by consuming poison, according to sources from t...254 last year," said J.R. Gaur, Director of the Hi...
...l and surgical services provided by NHS could suff...unties (Surrey and Sussex) failed to improve, warn...k financial management, in addition to lack of pro...th care trusts and hospitals is believed to reach ...
...spase-8 gene prevents the metastasis of the neurob...hildren's Research Hospital and the University of ... that have broken itself from the main primary tum... to all tumors present in the nervous system. It i...
...rus which causes severe diarrhea can be combated w.... The New England Journal of Medicine has publishe... much as by between 85% to 100%. The affliction af...ajor step towards getting them put into wider use....
...a: The Bird Flu outbreak is threatening to cause a...very crucial to contain the spread, according to t...burizal Bakrie. The Nation’s Economic Minister, eq...mic. The consequences would be extremely grave...
Other Medicine News:Health News:NHS Audit Commission Warns Possible Financial Collapse In Sussex And Surrey 2Health News:Metastasis of Neuroblastoma linked to Loss Of Caspase-8 gene 2
...ginal Vibratome Semi-Automatic Tissue Sectioning S...d tissue sectioning system. Researchers from aroun...sic for their fresh and fresh fixed tissue section...Automatic Tissue Sectioning Systems, the biologica...
...ratome 1000 Plus Sectioning System provides a vers...or plant tissues. The 1000 employs a vibrating bl...zing or embedding. The creation of artifacts, the...me activities, and other deleterious effects inher...
Specimen Mounting Blocks
Specimen Retrievers
Medicine Products: